Amedeo Smart

Free Medical Literature Service

 

Amedeo

Leukemia
  Free Subscription

Articles published in
Int J Hematol
    October 2025
  1. AKAHANE K, Kasai S, Tamai M, Sugita Y, et al
    Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome.
    Int J Hematol. 2025;122:611-615.
    >> Share

    September 2025
  2. TOMINAGA R, Fujiwara SI, Honda S, Yokoyama D, et al
    Significance of the tendency for relative bradycardia during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2025 Sep 18. doi: 10.1007/s12185-025-04070.
    >> Share

  3. HAN W, Wang S, Zhang M, Fu S, et al
    Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.
    Int J Hematol. 2025 Sep 10. doi: 10.1007/s12185-025-04064.
    >> Share

  4. TAKAHASHI H, Tanaka S, Yuza Y, Iijima-Yamashita Y, et al
    Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.
    Int J Hematol. 2025 Sep 4. doi: 10.1007/s12185-025-04060.
    >> Share

  5. ONO K, Horiguchi H, Iyama S, Sato K, et al
    Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms.
    Int J Hematol. 2025;122:400-412.
    >> Share

    August 2025
  6. LIU ZY, Yan ZY, Li JF, Zhu YM, et al
    Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.
    Int J Hematol. 2025;122:295-300.
    >> Share

    July 2025
  7. HAYASHINO K, Mochizuki N, Kawatsuki A, Fujiwara Y, et al
    Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.
    Int J Hematol. 2025 Jul 22. doi: 10.1007/s12185-025-04041.
    >> Share

  8. MAKISHIMA H, Mikasa T, Isogaya K, Miyamoto T, et al
    Association between gene mutations and outcomes in Japanese high-risk AML patients: a phase 1/2 study of NS-87/CPX-351.
    Int J Hematol. 2025;122:57-65.
    >> Share

    June 2025
  9. UYGUN A, Albayrak C, Ozgen U, Dincer OS, et al
    The role of leukapheresis in managing complications of hyperleukocytosis in pediatric acute leukemia.
    Int J Hematol. 2025 Jun 30. doi: 10.1007/s12185-025-04027.
    >> Share

  10. IMI T, Asakura H, Sato K, Yamada S, et al
    Transient lupus anticoagulant induced by adenovirus cystitis in a bone marrow transplant recipient.
    Int J Hematol. 2025 Jun 5. doi: 10.1007/s12185-025-04020.
    >> Share

  11. NOSAKA K, Fukushima T
    JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9-adult T-cell leukemia-lymphoma (ATL).
    Int J Hematol. 2025 Jun 4. doi: 10.1007/s12185-025-04011.
    >> Share

  12. MASUDA Y, Sadato D, Toya T, Hosoda Y, et al
    Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients.
    Int J Hematol. 2025;121:820-832.
    >> Share

    May 2025
  13. TAKAHASHI N, Kikushige Y, Nakamae H, Goto T, et al
    Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.
    Int J Hematol. 2025 May 26. doi: 10.1007/s12185-025-04014.
    >> Share

  14. KONISHI H, Tachibana T, Arai S, Izumi A, et al
    Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Int J Hematol. 2025 May 23. doi: 10.1007/s12185-025-04009.
    >> Share

  15. IKEDA J, Shiba N, Kato S, Kunimoto H, et al
    Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities.
    Int J Hematol. 2025;121:694-705.
    >> Share

  16. SAKURAI Y, Yanagimachi M, Ito M, Hirose A, et al
    A case of acute promyelocytic leukemia complicated by mitochondrial disease.
    Int J Hematol. 2025 May 1. doi: 10.1007/s12185-025-03992.
    >> Share

    April 2025
  17. OKA S, Akagi Y, Mituyoshi T, Ono K, et al
    Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patient.
    Int J Hematol. 2025 Apr 29. doi: 10.1007/s12185-025-03994.
    >> Share

  18. ITO T, Kamimura T, Kiguchi T, Kato K, et al
    Correction: Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.
    Int J Hematol. 2025 Apr 11. doi: 10.1007/s12185-025-03978.
    >> Share

  19. NGUYEN T, Harama D, Tamai M, Kagami K, et al
    Synergistic effect of asciminib with reduced doses of ponatinib in human Ph + myeloid leukemia with the T315M mutation.
    Int J Hematol. 2025 Apr 10. doi: 10.1007/s12185-025-03981.
    >> Share

  20. IZUTSU K, Ishikawa T, Shimada K, Kubo K, et al
    Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenstrom macroglobulinemia and CLL/SLL.
    Int J Hematol. 2025;121:483-493.
    >> Share

  21. TOKUSHIGE J, Taoka K, Nishikawa M, Jona M, et al
    Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria.
    Int J Hematol. 2025;121:543-546.
    >> Share

  22. NISHIWAKI S, Terakura S, Morishita T, Goto T, et al
    Post-transplant TKIs for Ph+ ALL: practices to date and clinical significance.
    Int J Hematol. 2025;121:494-503.
    >> Share

    March 2025
  23. KOH K, Kosaka Y, Okamoto Y, Maeda N, et al
    Phase 2 multicenter study of pegaspargase in Japanese patients with previously untreated acute lymphoblastic leukemia.
    Int J Hematol. 2025 Mar 31. doi: 10.1007/s12185-025-03976.
    >> Share

  24. NISHIMURA A, Tamura A, Fujikawa T, Inoue S, et al
    KMT2A-CBL fusion gene in the first reported case of T-cell acute lymphoblastic leukemia associated with Wiedemann-Steiner syndrome.
    Int J Hematol. 2025 Mar 28. doi: 10.1007/s12185-025-03975.
    >> Share

  25. YOSHIKAWA T, Ishida H, Watanabe A, Yuza Y, et al
    Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era.
    Int J Hematol. 2025 Mar 15. doi: 10.1007/s12185-025-03953.
    >> Share

  26. KAMIUNTEN A, Kameda T, Sekine M, Kawano H, et al
    Effects of tucidinostat in adult T-cell leukemia/lymphoma in clinical practice.
    Int J Hematol. 2025 Mar 11. doi: 10.1007/s12185-025-03963.
    >> Share

  27. TAKAMATSU Y
    JSH practical guidelines for hematological malignancies, 2023: leukemia-5. Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Int J Hematol. 2025 Mar 1. doi: 10.1007/s12185-025-03914.
    >> Share

    February 2025
  28. ABUMIYA M, Saito A, Fujioka Y, Miura M, et al
    Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia.
    Int J Hematol. 2025 Feb 25. doi: 10.1007/s12185-025-03954.
    >> Share

  29. ISHII S, Arakawa Y, Ishii H, Yokoyama K, et al
    A novel stroma-dependent leukemia cell line from a patient with mixed-phenotype acute leukemia with Ph chromosome and PAX5 mutation.
    Int J Hematol. 2025 Feb 20. doi: 10.1007/s12185-025-03944.
    >> Share

  30. MATSUMOTO Y, Kato D, Muramatsu A, Sugitani M, et al
    Karyotype evolution of myelodysplastic syndrome and acute myeloid leukemia with TP53 mutations.
    Int J Hematol. 2025 Feb 19. doi: 10.1007/s12185-025-03938.
    >> Share

    January 2025
  31. FENG LS, Li HY, Tang A, Xu ML, et al
    Venetoclax and azacitidine in combination with homoharringtonine, cytarabine, and aclarubicin for salvage therapy of relapsed/refractory T cell acute lymphoblastic leukemia.
    Int J Hematol. 2025 Jan 23. doi: 10.1007/s12185-025-03915.
    >> Share

  32. MIYAZAKI Y
    JSH practical guidelines for hematological malignancies, 2023: leukemia-6. Myelodysplastic syndromes (MDS).
    Int J Hematol. 2025 Jan 14. doi: 10.1007/s12185-024-03906.
    >> Share

  33. MIYAZAKI T, Uno S, Fujimori H, Motegi Y, et al
    Safety and effectiveness of lenalidomide in Japanese patients with relapsed/refractory ATLL: post-marketing surveillance.
    Int J Hematol. 2025;121:79-88.
    >> Share

  34. SAWA M, Miyamoto T, Kim HJ, Hiramatsu Y, et al
    A phase 1/2 study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia.
    Int J Hematol. 2025;121:56-67.
    >> Share

    December 2024
  35. CHIRIAC R
    Pseudo-Chediak-Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia.
    Int J Hematol. 2024 Dec 30. doi: 10.1007/s12185-024-03910.
    >> Share

  36. UTSUNOMIYA A, Yasunaga JI, Tabuchi T, Nakano N, et al
    A 25-year clonal resurrection in adult T-cell leukemia-lymphoma relapse.
    Int J Hematol. 2024 Dec 25. doi: 10.1007/s12185-024-03901.
    >> Share

  37. FUJITA H
    Correction: JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03908.
    >> Share

  38. MAEDA Y
    Correction: JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Dec 24. doi: 10.1007/s12185-024-03907.
    >> Share

  39. ARAI H, Hosono N, Chi S, Fukushima K, et al
    A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02.
    Int J Hematol. 2024 Dec 16. doi: 10.1007/s12185-024-03895.
    >> Share

  40. KOHSO A, Toyoda H, Hanaki R, Niwa K, et al
    Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia.
    Int J Hematol. 2024 Dec 9. doi: 10.1007/s12185-024-03890.
    >> Share

  41. INAMURA J, Taketani T, Mochida M, Goto T, et al
    Acute myeloid leukemia with NUP98::RARG rearrangement: a case report and review of the relevant literature.
    Int J Hematol. 2024 Dec 4. doi: 10.1007/s12185-024-03881.
    >> Share

  42. SHIMONODAN H, Sakaguchi K, Ishihara T, Okamoto Y, et al
    Silent inactivation of asparaginase in Japan: results of the prospective ALL-ASP19 trial.
    Int J Hematol. 2024;120:725-734.
    >> Share

    November 2024
  43. TAKAHASHI N, Takenaka K, Iriyama N, Kirito K, et al
    JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03865.
    >> Share

  44. MUTA T, Masamoto Y, Yamamoto G, Kurahashi S, et al
    Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.
    Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03875.
    >> Share

  45. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.
    Int J Hematol. 2024 Nov 25. doi: 10.1007/s12185-024-03880.
    >> Share

  46. ISHII Y, Fujisawa S, Miyazaki T, Nakajima Y, et al
    Real-world toxicity and efficacy of asciminib in heavily pretreated patients with chronic myeloid leukemia.
    Int J Hematol. 2024 Nov 19. doi: 10.1007/s12185-024-03873.
    >> Share

  47. SABURI M, Nishikawa T, Kawano K, Ohtsuka E, et al
    Successful complete remission after induction therapy with CPX-351 for acute myeloid leukemia with myelodysplasia-related changes accompanied by double-minute chromosomes and MYC gene amplification.
    Int J Hematol. 2024 Nov 11. doi: 10.1007/s12185-024-03876.
    >> Share

  48. NAKA R, Shimomura Y, Miura M, Nagai Y, et al
    Safety and efficacy of asciminib in a patient with chronic myeloid leukemia on hemodialysis.
    Int J Hematol. 2024 Nov 7. doi: 10.1007/s12185-024-03869.
    >> Share

  49. ISHIKAWA Y
    Recent progress in AML with recurrent genetic abnormalities.
    Int J Hematol. 2024;120:525-527.
    >> Share

  50. SUGIURA H, Ishikawa T, Kuroi T, Okamoto S, et al
    Comparison of disease and risk classifications of AML before and after incorporation of NGS analysis of bone marrow samples.
    Int J Hematol. 2024;120:594-600.
    >> Share

  51. ISHIKAWA Y, Ushijima Y, Kiyoi H
    Recent advances in AML with mutated NPM1.
    Int J Hematol. 2024;120:556-565.
    >> Share

  52. KENNEDY VE, Smith CC
    FLT3 targeting in the modern era: from clonal selection to combination therapies.
    Int J Hematol. 2024;120:528-540.
    >> Share

    October 2024
  53. OUCHI F, Shingai N, Najima Y, Sadato D, et al
    Quizartinib with donor lymphocyte infusion for post-transplant relapse of FLT3-ITD-positive acute myeloid leukemia.
    Int J Hematol. 2024 Oct 26. doi: 10.1007/s12185-024-03863.
    >> Share

  54. HASHIMOTO M, Kato T, Yokota K, Sakamoto H, et al
    Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy.
    Int J Hematol. 2024 Oct 10. doi: 10.1007/s12185-024-03857.
    >> Share

  55. CHIRIAC R
    Therapy-related acute myeloid leukemia with inv(16)(p13.1q22).
    Int J Hematol. 2024 Oct 8. doi: 10.1007/s12185-024-03858.
    >> Share

  56. URRUTIA S, Takahashi K
    Precision medicine in AML: overcoming resistance.
    Int J Hematol. 2024;120:439-454.
    >> Share

  57. YOSHIMARU R, Minami Y
    Achievement of deep molecular response and treatment-free remission with asciminib treatment in CML.
    Int J Hematol. 2024;120:512-514.
    >> Share

  58. SAITO S, Nakazawa Y
    CAR-T cell therapy in AML: recent progress and future perspectives.
    Int J Hematol. 2024;120:455-466.
    >> Share

    September 2024
  59. KINOSHITA M, Saito Y, Otani K, Uehara Y, et al
    Mitochondrial dynamics as a potential therapeutic target in acute myeloid leukemia.
    Int J Hematol. 2024 Sep 16. doi: 10.1007/s12185-024-03843.
    >> Share

  60. HATTA Y, Izutsu K, Onizuka M, Dobashi N, et al
    JSH practical guidelines for hematological malignancies, 2023: leukemia-3. Acute lymphoblastic leukemia/lymphoblastic lymphoma: ALL/LBL.
    Int J Hematol. 2024 Sep 6. doi: 10.1007/s12185-024-03836.
    >> Share

  61. YAMAGUCHI H
    Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia.
    Int J Hematol. 2024 Sep 3. doi: 10.1007/s12185-024-03837.
    >> Share

  62. MINAMI Y, Doki N, Matsuoka H, Yokota T, et al
    Asciminib in Patients With CML-CP Previously Treated With >/= 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Int J Hematol. 2024;120:305-313.
    >> Share

  63. SUZUKI K, Koyama D, Oka Y, Sato Y, et al
    Myeloid sarcoma with plasmacytoid dendritic cell-like proliferation associated with IKZF1, ETV6 and DNMT3A mutations.
    Int J Hematol. 2024;120:382-388.
    >> Share

    August 2024
  64. NISHIJIMA M, Ido K, Okayama Y, Okamura H, et al
    A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion.
    Int J Hematol. 2024 Aug 30. doi: 10.1007/s12185-024-03839.
    >> Share

  65. GOTO H, Kada A, Ogawa C, Nishiuchi R, et al
    Treatment of relapsed acute lymphoblastic leukemia in children: an observational study of the Japan Children's Cancer Group.
    Int J Hematol. 2024 Aug 27. doi: 10.1007/s12185-024-03838.
    >> Share

  66. ITO T, Kamimura T, Kiguchi T, Kato K, et al
    Venetoclax treatment for chronic lymphocytic leukemia/small lymphocytic leukemia in Japan: post-marketing surveillance.
    Int J Hematol. 2024 Aug 21. doi: 10.1007/s12185-024-03832.
    >> Share

  67. NAGATA Y
    Molecular pathophysiology of germline mutations in acute myeloid leukemia.
    Int J Hematol. 2024 Aug 16. doi: 10.1007/s12185-024-03824.
    >> Share

  68. URESHINO H, Takahashi N, Ikezoe T, Kameoka Y, et al
    A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).
    Int J Hematol. 2024 Aug 13. doi: 10.1007/s12185-024-03830.
    >> Share

  69. OYA S, Ozawa H, Nakamura T, Mori A, et al
    CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
    Int J Hematol. 2024;120:194-202.
    >> Share

  70. LU Y, Ma WB, Ren GM, Li YT, et al
    GPS2 promotes erythroid differentiation in K562 erythroleukemia cells primarily via NCOR1.
    Int J Hematol. 2024;120:157-166.
    >> Share

  71. ZHANG W, Li J, Yamamoto K, Goyama S, et al
    Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency.
    Int J Hematol. 2024;120:186-193.
    >> Share

    July 2024
  72. IKEDA S, Suzuki M, Tsunoda S, Ohta M, et al
    Dynamic changes in femoral bone marrow MRI in patients with chronic myelogenous leukemia.
    Int J Hematol. 2024 Jul 15. doi: 10.1007/s12185-024-03819.
    >> Share

  73. KUROSAWA S, Nakazato T
    Immunohistochemical differentiation of extramedullary acute myeloid leukemia from blastic plasmacytoid dendritic cell neoplasm.
    Int J Hematol. 2024 Jul 10. doi: 10.1007/s12185-024-03817.
    >> Share

  74. OYA S, Ozawa H, Morishige S, Maehiro Y, et al
    High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
    Int J Hematol. 2024 Jul 4. doi: 10.1007/s12185-024-03814.
    >> Share

  75. SAJIKI D, Yoshida N, Muramatsu H, Sakaguchi K, et al
    Clinical features of immature leukemias in children.
    Int J Hematol. 2024;120:117-127.
    >> Share

    May 2024
  76. GONZALEZ-MANCERA MS, Lopategui J, Hoffman D, Kitahara S, et al
    B-cell prolymphocytic leukemia: an enduring bona fide entity.
    Int J Hematol. 2024 May 26. doi: 10.1007/s12185-024-03774.
    >> Share

  77. ARAI S, Tachibana T, Izumi A, Takeda T, et al
    WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
    Int J Hematol. 2024 May 25. doi: 10.1007/s12185-024-03795.
    >> Share

  78. SHI X, Feng M, Nakada D
    Metabolic dependencies of acute myeloid leukemia stem cells.
    Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03789.
    >> Share

  79. AKIYAMA H, Kantarjian H, Jabbour E, Issa G, et al
    Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia.
    Int J Hematol. 2024 May 15. doi: 10.1007/s12185-024-03787.
    >> Share

  80. KAITO Y, Imai Y
    Evolution of natural killer cell-targeted therapy for acute myeloid leukemia.
    Int J Hematol. 2024 May 1. doi: 10.1007/s12185-024-03778.
    >> Share

  81. ITO M, Fukushima N
    Faggot cells observed in a patient with myelodysplastic syndrome with increased blasts.
    Int J Hematol. 2024;119:476-478.
    >> Share

    April 2024
  82. KATSUKI K, Tachibana T, Izumi A, Kim K, et al
    Acute mixed-lineage leukemia treated with desensitization therapy prior to HLA-haploidentical transplantation with high donor-specific antibodies.
    Int J Hematol. 2024 Apr 27. doi: 10.1007/s12185-024-03775.
    >> Share

  83. TIEN FM, Hou HA
    CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.
    Int J Hematol. 2024 Apr 26. doi: 10.1007/s12185-024-03773.
    >> Share

  84. FUJITA H
    JSH practical guidelines for hematological malignancies, 2023: leukemia-2-acute promyelocytic leukemia (APL).
    Int J Hematol. 2024 Apr 17. doi: 10.1007/s12185-024-03749.
    >> Share

  85. IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al
    Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
    Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
    >> Share

  86. TODA Y, Ashizawa M, Murahashi R, Nakashima H, et al
    Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
    Int J Hematol. 2024 Apr 5. doi: 10.1007/s12185-024-03752.
    >> Share

  87. NAKAMURA T, Oya S, Ozawa H, Maehiro Y, et al
    Correlation of ex vivo and in vivo ammonia production with L-asparaginase biological activity in adults with lymphoid malignancies.
    Int J Hematol. 2024;119:426-431.
    >> Share

    March 2024
  88. USUKI K, Miyamoto T, Yamauchi T, Ando K, et al
    A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733.
    >> Share

  89. XU J, Zong S, Sheng T, Zheng J, et al
    Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.
    Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03732.
    >> Share

  90. IOANNIDOU M, Avgeros C, Georgiou E, Papadimitriou-Tsantarliotou A, et al
    Effect of apolipoprotein E (APOE) gene polymorphisms on the lipid profile of children being treated for acute lymphoblastic leukemia.
    Int J Hematol. 2024 Mar 20. doi: 10.1007/s12185-024-03748.
    >> Share

  91. TAKIZAWA J, Suzuki R, Izutsu K, Kiguchi T, et al
    Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03741.
    >> Share

  92. KAWAKAMI Y, Imamura M, Imai C
    Isolated salivary gland extramedullary relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia during blinatumomab treatment.
    Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03756.
    >> Share

  93. MAEDA Y
    JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
    >> Share

  94. SANO H, Fukushima K, Yano M, Osone S, et al
    Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
    Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
    >> Share

  95. XUE S, Sun HP, Huang XB, Chen X, et al
    Characteristics and literature review of ETV6::ABL1 fusion gene-positive acute myeloid leukemia.
    Int J Hematol. 2024 Mar 5. doi: 10.1007/s12185-024-03729.
    >> Share

  96. AN K, He Y, Tang Y, Gu X, et al
    Histiocytic sarcoma following CAR T-cell therapy: a case report.
    Int J Hematol. 2024;119:338-341.
    >> Share

    February 2024
  97. SHIOZAWA Y, Fujita S, Nannya Y, Ogawa S, et al
    First report of familial mixed phenotype acute leukemia: shared clinical characteristics, Philadelphia translocation, and germline variants.
    Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03724.
    >> Share

  98. CHOED-AMPHAI C, Khorana J, Sathitsamitphong L, Natesirinilkul R, et al
    Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2024 Feb 29. doi: 10.1007/s12185-024-03725.
    >> Share

  99. YOKOYAMA Y
    Risk factors and remaining challenges in the treatment of acute promyelocytic leukemia.
    Int J Hematol. 2024 Feb 22. doi: 10.1007/s12185-023-03696.
    >> Share

  100. HISADA Y
    Dysregulated hemostasis in acute promyelocytic leukemia.
    Int J Hematol. 2024 Feb 11. doi: 10.1007/s12185-024-03708.
    >> Share

  101. YANAGI M, Mori M, Honda M, Mitani Y, et al
    Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
    Int J Hematol. 2024 Feb 1. doi: 10.1007/s12185-023-03701.
    >> Share

  102. MARUYAMA D, Omi A, Nomura F, Touma T, et al
    Real-world effectiveness and safety of ibrutinib in relapsed/refractory mantle cell lymphoma in Japan: post-marketing surveillance.
    Int J Hematol. 2024;119:146-155.
    >> Share

  103. SCHALK E, Pelz AF
    Auer rods in mature granulocytes in peripheral blood.
    Int J Hematol. 2024;119:105-106.
    >> Share

  104. USUKI K, Ohtake S, Honda S, Matsuda M, et al
    Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Int J Hematol. 2024;119:130-145.
    >> Share

    January 2024
  105. UEKI H, Ogawa C, Goto H, Nishi M, et al
    TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.
    Int J Hematol. 2024 Jan 25. doi: 10.1007/s12185-024-03710.
    >> Share

  106. OKAYAMA Y, Harada N, Makuuchi Y, Kuno M, et al
    Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission.
    Int J Hematol. 2024 Jan 22. doi: 10.1007/s12185-023-03707.
    >> Share

  107. KATO K, Takagi S, Takano H, Tsunoda S, et al
    A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia.
    Int J Hematol. 2024 Jan 18. doi: 10.1007/s12185-023-03691.
    >> Share

  108. OYAKE M, Hirakuni Y, Hirano N, Suenobu S, et al
    Abnormal bone marrow T1-weighted MRI images in a pediatric patient with acute lymphoblastic leukemia without peripheral blasts.
    Int J Hematol. 2024 Jan 3. doi: 10.1007/s12185-023-03697.
    >> Share

  109. USUKI K, Ohtake S, Honda S, Matsuda M, et al
    Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Int J Hematol. 2024;119:24-38.
    >> Share

  110. ITO M, Fukushima N, Fujii T, Numata M, et al
    Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2024;119:80-87.
    >> Share

    December 2023
  111. MAKITA S, Ota S, Mishima Y, Usuki K, et al
    Japanese phase Ib study of the oral PI3K-delta and -gamma inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Int J Hematol. 2023 Dec 27. doi: 10.1007/s12185-023-03689.
    >> Share

  112. ZHAO B, Yin J, Ding L, Luo J, et al
    SPAG6 regulates cell proliferation and apoptosis via TGF-beta/Smad signal pathway in adult B-cell acute lymphoblastic leukemia.
    Int J Hematol. 2023 Dec 26. doi: 10.1007/s12185-023-03684.
    >> Share

  113. NUKUI J, Tachibana T, Miyazaki T, Tanaka M, et al
    Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2023 Dec 12. doi: 10.1007/s12185-023-03688.
    >> Share

  114. TAKEYASU S, Morita K, Saito S, Toho M, et al
    Myeloid sarcoma and pathological fracture: a case report and review of literature.
    Int J Hematol. 2023;118:745-750.
    >> Share

  115. MIKI K, Ogasawara R, Sugimura S, Sugita J, et al
    A case of Hodgkin lymphoma-type Richter syndrome presenting as small-intestinal perforation.
    Int J Hematol. 2023;118:766-771.
    >> Share

    November 2023
  116. SHIOMI I, Nakako S, Nakane T, Ogawa Y, et al
    Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
    Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678.
    >> Share

  117. SAKAI Y, Ikawa Y, Takenaka M, Noguchi K, et al
    Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis.
    Int J Hematol. 2023 Nov 21. doi: 10.1007/s12185-023-03675.
    >> Share

    October 2023
  118. FUKATSU M, Hamazaki Y, Sato Y, Koyama D, et al
    A case of cold agglutinin syndrome associated with chronic lymphocytic leukaemia harbouring mutations in CARD11 and KMT2D.
    Int J Hematol. 2023;118:472-476.
    >> Share

  119. UNO S, Motegi Y, Minehata K, Aoki Y, et al
    Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
    Int J Hematol. 2023;118:432-442.
    >> Share

    September 2023
  120. ZHANG A, Liu L, Zong S, Chang L, et al
    Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 x 10(9)/L.
    Int J Hematol. 2023 Sep 21. doi: 10.1007/s12185-023-03665.
    >> Share

  121. HARA R, Machida S, Hashimoto N, Ogiya D, et al
    Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax.
    Int J Hematol. 2023 Sep 20. doi: 10.1007/s12185-023-03664.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016